Latest News

Please view the latest news articles from across Europe below. Alternatively, filter by news category or search by keyword.

Meet Colossus...

Published on 20 February 2018 back to previous

Colorectal cancer is the third most prevalent cancer in Europe. Of total CRC cases, approximately 50-55% involve mutations in a gene called RAS. Current treatments for  RAS mutant metastatic CRC include fluorouracil based chemotherapy +/- bevacizumab. However, limitations exist for patients with this type of CRC in that in time they largely become resistant to  standard treatments


COLOSSUS is an EC-funded H2020 project that aims to provide new, more effective ways to classify patients with RAS mutant metastatic CRC,  and to develop new targeted treatment options. 

COLOSSUS will employ multi-omic computational modelling approaches to study and group RAS  mutant CRC into novel subtypes and will thus seek to develop new personalised treatments for these patients

To learn more about the project, please visit

Join our conversation on Twitter @COLOSSUSEU and please follow us on Facebook COLOSSUS Project.

Registration No: 5314195 Registered Office: 92 Palatine Road, London N16 8ST.